Despite a decrease in milestone revenue, Growject\u00ae progress is on schedule and Iscargo\u00ae is performing well. Full-year forecasts are maintained, but operating profit is expected to decline significantly due to increased R&D expenses. Domestic and international rollout of givinostat and new drug out-licensing will support medium- to long-term growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4552-20261029-01.pdf","jir_short_summary":"Despite a decrease in milestone revenue, Growject\u00ae progress is on schedule and Iscargo\u00ae is performing well. Full-year forecasts are maintained, but operating profit is expected to decline significantly due to increased R&D expenses. Domestic and international rollout of givinostat and new drug out-licensing will support medium- to long-term growth.","jir_summary":"### Earnings Overview\nThis summarizes results for the six months ended March 2026 and key points of the full-year forecast for the fiscal year ending March 2027. Revenue declined year-over-year, impacted by delays in milestone payments. Growject\u00ae continues expansion in the domestic market, and Iscargo\u00ae is introducing new cases smoothly. R&D expenses are trending upward, which could result in an upside to the full-year forecast, although overall SG&A will be managed to stay near plan. Introduction and development of givinostat are progressing domestically and internationally.\n\n### Outlook and Impact for Investors\nThe full-year forecast is unchanged for now, but milestone revenue progress could lead to upside, while increased R&D spending and foreign exchange effects are expected to keep operating income under pressure. License income domestically and internationally and growth via JVs are expected to support mid-term revenue growth. M&A and partnerships for technology out-licensing remain important growth drivers to monitor.","jir_financial_highlights":"Revenue: 19,974 (Year-over-Year -6.5%)\nOperating Income: -3,504 (Year-over-Year -5,934)\nResearch and Development Expenses: 10,230 (Year-over-Year +2,395)\nMilestone Revenue: 1,474 (Year-over-Year -3,540)\nGrowject Domestic Market Share (reference): Unknown (Unknown)","jir_category":"","jir_hashtags":"#JCRPharmaceuticalsIsPublicIR #EarningsAnnouncement #JapaneseStocks","jir_key_figures":"Revenue: 19,974 million yen (Year-over-Year -6.5%)\nOperating Income: -3,504 million yen\nResearch and Development Expenses: 10,230 million yen (Year-over-Year +2,395)","jir_meta_title":"JCR Pharmaceuticals Co., Ltd. | Life is Rare \u2014 FY2027 Q2 Earnings","jir_meta_description":"Summary of JCR Pharmaceuticals Co., Ltd.'s FY2027 Q2 results: trends in revenue, milestone income and R&D expenses, outlook for the full year, and key points on domestic and international strategy centered on givinostat.","jir_og_title":"Key Points from JCR Pharmaceuticals Q2 Earnings","jir_og_description":"Milestone revenue trends and increased R&D spending affecting results. Progress of Growject, Iscargo and domestic\/international development of givinostat are key to medium-term growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2026-06\\\",\\\"2026-09\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[21362,19974,?,19974],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2026-06\\\",\\\"2026-09\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2429,-3504,-3504,-3504],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Gross Profit Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Profit Margin\\\",\\\"data\\\":[80.2,?],\\\"backgroundColor\\\":\\\"#3cba9f\\\"}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Composition by Drug\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Growject\\\",\\\"Izcargo\\\",\\\"Temcell HS Injection\\\",\\\"Renal Anemia Treatment\\\",\\\"Agalcidase Beta\\\"],\\\"datasets\\\":[{\\\"data\\\":[? , ?, ?, ?, ?],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\",\\\"#59a14f\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Full-Year Forecast and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":[],\\\"options\\\":{}}\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136609","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n